Restoring Metabolic Balance.

Transforming Lives.

Developing medicines to reverse the course of serious metabolic diseases.

NASH: A Life-Threatening Liver Disease

NASH (non-alcoholic steatohepatitis) is rapidly emerging as the leading cause of liver disease around the world, driven by the growing global epidemic of obesity and diabetes. NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver cell (hepatocyte) damage, liver inflammation, and fibrosis that can progress to cirrhosis, liver failure, cancer and death.

MORE ABOUT NASH
Abstract Illustration of Liver
Illustration of AKR-001

Our Lead Candidate: AKR-001

AKR-001 is an investigational treatment for NASH being evaluated in a Phase 2 clinical trial. AKR-001 is engineered to harness the inherent benefits of a naturally-occurring hormone called FGF21 with once-weekly subcutaneous dosing. AKR-001 addresses both the underlying metabolic drivers of NASH and the downstream consequences of inflammation and fibrosis.

More About AKR-001

Delivering Transformational Therapies for Patients

Akero Therapeutics is a clinical-stage company led by a team of industry veterans dedicated to developing transformational therapies for serious metabolic diseases. Our initial focus is NASH, a serious and rapidly-growing condition for which there is no approved treatment.

More About Akero

In the News

September 4, 2019

AKERO THERAPEUTICS TO PRESENT AT THE MORGAN STANLEY 17TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

A clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that members of the management team will provide a business overview and update at the Morgan Stanley 17th Annual Global Healthcare Conference at 5:25 p.m. ET on Monday, September 9, 2019 in New York, NY.

Read More

August 12, 2019

AKERO THERAPEUTICS REPORTS RECENT HIGHLIGHTS AND SECOND QUARTER 2019 FINANCIAL RESULTS

— Advanced AKR-001 into Phase 2a BALANCED clinical study in NASH —— Raised $98.4 million in aggregate net proceeds from Initial Public Offering — SAN FRANCISCO, Aug. 12, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today provided a business update and […]

Read More

July 2, 2019

Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)

A clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced

Read More

June 24, 2019

AKERO THERAPEUTICS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND EXERCISE IN FULL OF THE UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES

Akero Therapeutics, Inc. (Nasdaq:AKRO), a clinical-stage biotechnology company developing transformational…

Read More

June 19, 2019

AKERO THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic…

Read More

May 29, 2019

Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH

Akero Therapeutics announced today that it has screened the first patient for its Phase 2a clinical trial evaluating AKR-001, the company’s lead product candidate for the treatment of NASH.

Read More

Read More News

© 2019 Akero Therapeutics, Inc. All rights reserved. Terms of Use.